Outlook maintained for the full-year – soft quarter
We delivered an improved EBITA margin supported by good sales in Neuro and Oncology Informatics as well as by our cost reduction program. However, the third quarter was disappointing from an order perspective as the U.S. business did not live up to our expectations. Our order pipeline of Elekta Unity is strong, which ensures that the order target will be met – most likely already in the fourth quarter.
Richard Hausmann
President and CEO
Third quarter
Significant events after the quarter
1 After continuous investments
2 Before/after dilution
3 Compared to last fiscal year based on constant currency
Outlook for fiscal year 2019/20
# # #
For further information, please contact:
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time
Gustaf Salford, CFO
Tel: +46 70 216 17 50, e-mail: gustaf.salford@elekta.com
Time zone: CET: Central European Time
This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on February 20, 2020. (REGMAR)
About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25,
E-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time
Gustaf Salford, CFO
Tel: +46 70 216 17 50,
E-mail: gustaf.salford@elekta.com
Time zone: CET: Central European Time